{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T16:01:19Z","timestamp":1720627279724},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00108-019-00669-z","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T14:42:58Z","timestamp":1567780978000},"page":"1215-1220","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rolle der Januskinaseinhibitoren in der Therapie rheumatischer Erkrankungen"],"prefix":"10.1007","volume":"60","author":[{"given":"K.","family":"Kr\u00fcger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"669_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen\u00a0JS, van der Heijde\u00a0D, Machold\u00a0KP et al (2014) Proposal for a\u00a0new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73:3\u20135","journal-title":"Ann Rheum Dis"},{"key":"669_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz\u00a0DM, Kanno\u00a0Y, Villarino\u00a0A et\u00a0al (2017) JAK inhibition as a\u00a0therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:843\u2013862","journal-title":"Nat Rev Drug Discov"},{"key":"669_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","volume":"10","author":"CJ Malemud","year":"2018","unstructured":"Malemud\u00a0CJ (2018) The role of the JAK\/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 10:117\u2013127","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"669_CR4","first-page":"953","volume":"58","author":"EH Choy","year":"2019","unstructured":"Choy\u00a0EH (2019) Clinical significance of Janus Kinase inhibitor selectivity. Baillieres Clin Rheumatol 58:953\u2013962","journal-title":"Baillieres Clin Rheumatol"},{"key":"669_CR5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon\u00a0S (2017) Tofacitinib: a review in rheumatoid arthritis. Drugs 77:1987\u20132001","journal-title":"Drugs"},{"key":"669_CR6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee\u00a0EB, Fleischmann\u00a0R, Hall\u00a0S et\u00a0al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N\u00a0Engl J Med 370:2377\u20132386","journal-title":"N Engl J Med"},{"key":"669_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer\u00a0J, Li\u00a0ZG, Hall\u00a0S et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a\u00a0randomized trial. Ann Intern Med 159:253\u2013261","journal-title":"Ann Intern Med"},{"issue":"9865","key":"669_CR8","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester\u00a0GR, Blanco\u00a0R, Charles-Schoeman\u00a0C et al (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a\u00a0randomised phase 3 trial. Lancet 381(9865):451\u2013460","journal-title":"Lancet"},{"key":"669_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt\u00a0J, Lee\u00a0EB, Curtis\u00a0JR et al (2019) Safety and efficacy of\u00a0tofacitinib\u00a0for up to 9.5\u2009years in the treatment of rheumatoid arthritis: final results of a\u00a0global, open-label, long-term extension study. Arthritis Res Ther 21:89","journal-title":"Arthritis Res Ther"},{"key":"669_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde\u00a0D, Tanaka\u00a0Y, Fleischmann\u00a0R et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a\u00a0twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559\u2013570","journal-title":"Arthritis Rheum"},{"key":"669_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/acr.23004","volume":"69","author":"V Strand","year":"2017","unstructured":"Strand\u00a0V, Kremer\u00a0JM, Gruben\u00a0D et al (2017) Tofacitinib\u00a0in combination with conventional disease-modifying Antirheumatic drugs in patients with active\u00a0rheumatoid arthritis:\u00a0patient-reported\u00a0outcomes from a\u00a0phase III randomized controlled trial. Arthritis Care Res 69:592\u2013598","journal-title":"Arthritis Care Res"},{"issue":"10093","key":"669_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Mysler\u00a0E, Hall\u00a0S et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a\u00a0phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468","journal-title":"Lancet"},{"issue":"Suppl 10","key":"669_CR13","first-page":"1609","volume":"68","author":"S Hall","year":"2016","unstructured":"Hall\u00a0S, Nash\u00a0P, Rischmueller\u00a0M et al (2016) Efficacy of tofacitinib in patients who are inadequate responders to disease-modifying antirheumatic drugs according to early versus late duration ofbrheumatoid arthritis: post-hoc analysis of data from phase 3 trials. Arthritis Rheumatol 68(Suppl 10):1609","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl. 10","key":"669_CR14","first-page":"424","volume":"69","author":"J Kaine","year":"2017","unstructured":"Kaine\u00a0J, Tesser\u00a0J, DeMasi\u00a0R et al (2017) Re-establishment of efficacy of Tofacitinib, an oral Janus Kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation. Arthritis Rheum 69(Suppl. 10):424","journal-title":"Arthritis Rheum"},{"issue":"Suppl 10","key":"669_CR15","first-page":"2371","volume":"69","author":"A Dikranian","year":"2017","unstructured":"Dikranian\u00a0A, Gonzalez-Gay\u00a0MA, Wellborne\u00a0F et al (2017) The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index. Arthritis Rheumatol 69(Suppl 10):2371","journal-title":"Arthritis Rheumatol"},{"key":"669_CR16","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama\u00a0ZT, Scott\u00a0LJ (2018) Baricitinib: a review in rheumatoid arthritis. Drugs 78:761\u2013772","journal-title":"Drugs"},{"key":"669_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados\u00a0M, van der Heijde\u00a0D, Chen\u00a0YC et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88\u201395","journal-title":"Ann Rheum Dis"},{"key":"669_CR18","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese\u00a0MC, Kremer\u00a0J, Zamani\u00a0O et\u00a0al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N\u00a0Engl J Med 374:1243\u20131252","journal-title":"N Engl J Med"},{"key":"669_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor\u00a0PC, Keystone\u00a0EC, van der Heijde\u00a0D et\u00a0al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N\u00a0Engl J Med 376:652\u2013662","journal-title":"N Engl J Med"},{"key":"669_CR20","doi-asserted-by":"publisher","first-page":"e000898","DOI":"10.1136\/rmdopen-2019-000898","volume":"5","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde\u00a0D, Schiff\u00a0M, Tanaka\u00a0Y et\u00a0al (2019) Low rates of radiographic progression of structural joint damage over 2 years of\u00a0baricitinibtreatment in patients with rheumatoid arthritis. RMD Open 5:e898. \n                    https:\/\/doi.org\/10.1136\/rmdopen-2019-000898","journal-title":"RMD Open"},{"key":"669_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann\u00a0R, Schiff\u00a0M, van der Heijde\u00a0D et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506\u2013517","journal-title":"Arthritis Rheumatol"},{"key":"669_CR22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3899\/jrheum.161161","volume":"45","author":"EC Keystone","year":"2018","unstructured":"Keystone\u00a0EC, Genovese\u00a0MC, Schlichting\u00a0DE et al (2018) Safety and efficacy of\u00a0Baricitinib\u00a0through 128 weeks in an open-label, Longterm\u00a0extension\u00a0study in patients with rheumatoid arthritis. J\u00a0Rheumatol 45:14\u201321","journal-title":"J Rheumatol"},{"key":"669_CR23","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/annrheumdis-2018-213271","volume":"78","author":"T Takeuchi","year":"2019","unstructured":"Takeuchi\u00a0T, Genovese\u00a0MC, Haraoui\u00a0B et\u00a0al (2019) Dose\u00a0reduction\u00a0of\u00a0baricitinib\u00a0in patients with rheumatoid arthritis achieving sustained disease control: results of a\u00a0prospective study. Ann Rheum Dis 78:171\u2013178","journal-title":"Ann Rheum Dis"},{"key":"669_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/art.41032","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann\u00a0R, Pangan\u00a0AL, Song\u00a0IH et al (2019) Upadacitinib versus placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to Methotrexate: results of a\u00a0phase 3, double-blind, randomized controlled trial. Arthritis Rheum. \n                    https:\/\/doi.org\/10.1002\/art.41032\n                    \n                   (online July 4)","journal-title":"Arthritis Rheum"},{"key":"669_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese\u00a0MC, Kalunian\u00a0K, Gottenberg\u00a0JE et al (2019) Effect of\u00a0Filgotinib\u00a0vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying Antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 322:315\u2013325","journal-title":"JAMA"},{"key":"669_CR26","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17512433.2019.1615443","volume":"12","author":"Q Qiu","year":"2019","unstructured":"Qiu\u00a0Q, Feng\u00a0Q, Tan\u00a0X, Guo\u00a0M (2019) JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Pharmacol 12:547\u2013554","journal-title":"Expert Rev Clin Pharmacol"},{"key":"669_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen\u00a0JS, Breedveld\u00a0FC, Burmester\u00a0GR et\u00a0al (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75:3\u201315","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"669_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et al (2018) S2e-Leitlinie: Behandlung der rheumatoiden Arthritis mit krankheitsmodifizierenden Medikamenten. Z\u00a0Rheumatol 77(Suppl 2):35\u201353","journal-title":"Z Rheumatol"},{"key":"669_CR29","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease\u00a0P, Hall\u00a0S, FitzGerald\u00a0O et\u00a0al (2017) Tofacitinib or Adalimumab versus placebo for Psoriatic arthritis. N\u00a0Engl J Med 377:1537\u20131550","journal-title":"N Engl J Med"},{"key":"669_CR30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman\u00a0D, Rigby\u00a0W, Azevedo\u00a0VF et\u00a0al (2017) Tofacitinib\u00a0for\u00a0Psoriatic arthritis\u00a0in patients with an inadequate response to TNF inhibitors. N\u00a0Engl J Med 377:1525\u20131536","journal-title":"N Engl J Med"},{"key":"669_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen\u00a0JS, Genovese\u00a0MC, Takeuchi\u00a0T et\u00a0al (2019) Safety profile of Baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J\u00a0Rheumatol 46:7\u201318","journal-title":"J Rheumatol"},{"key":"669_CR32","unstructured":"Rote Hand Brief vom 22.5.19: XELJANZ (Tofacitinib): Einschr\u00e4nkung der Anwendung von zweimal t\u00e4glich 10\u202fmg bei Patienten mit erh\u00f6htem Risiko f\u00fcr Lungenembolien"},{"key":"669_CR33","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop\u00a0KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234\u2013243","journal-title":"Nat Rev Rheumatol"},{"key":"669_CR34","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie f\u00fcr Baricitinib und Tofacitinib (2019) Therapiebegleitbl\u00e4tter. \n                    dgrh.de\/Start\/Versorgung\/Therapie\u00fcberwachung\/Therapie\u00fcberwachungsb\u00f6gen.html\n                    \n                  . Zugegriffen: 30.7.2019"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00669-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-00669-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-00669-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T23:22:54Z","timestamp":1599175374000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-00669-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["669"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-00669-z","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]},"assertion":[{"value":"5 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Kr\u00fcger hat Honorare f\u00fcr Beratung und Vortr\u00e4ge erhalten von: AbbVie, BMS, Lilly, Medac, MSD, Pfizer, Roche, Sanofi, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}